OncoMatch/Clinical Trials/NCT06033820
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
Is NCT06033820 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies ZR2-ICE for diffuse large b-cell lymphoma recurrent.
Treatment: ZR2-ICE — This is a prospective, single center, single arm, open label study of zanubrutinib, lenalidomide in combination with Rituximab-ICE for treatment of relapsed/refractory diffuse large B-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 positive
CD20 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CD20-targeted therapy
one therapy line must have included a CD20-targeted therapy
Cannot have received: autologous stem cell transplant
Exception: allowed if >3 months prior to consent
have undergone ASCT within the period ≤3 months prior to signing the informed consent form
Cannot have received: allogenic stem cell transplantation
have undergone previous allogenic stem cell transplantation
Lab requirements
Blood counts
ANC ≥1.5 x 10^9/L or ≥0.75 x 10^9/L if bone marrow involvement; Platelets ≥90 x 10^9/L or ≥50 x 10^9/L if bone marrow involvement; Hemoglobin ≥75 g/dL or ≥50 g/dL if bone marrow involvement
Kidney function
Creatinine Clearance Rate ≥60 mL/min
Liver function
Total bilirubin ≤2.5 x ULN unless due to Gilbert's syndrome or hepatic involvement; ALT, AST, ALP ≤3 x ULN or <5 x ULN if hepatic involvement
Patients must meet the following laboratory criteria at screening, including: Absolute neutrophil count (ANC) ≥1.5 x 10^9/L or ≥0.75 x 10^9/L if bone marrow involvement; Platelets ≥90 x 10^9/L or ≥50 x 10^9/L if bone marrow involvement; Hemoglobin ≥75 g/dL or ≥50 g/dL if bone marrow involvement; Total bilirubin ≤2.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of hepatic involvement. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤3 x (ULN) or < 5 x ULN if hepatic involvement. Creatinine Clearance Rate ≥60 mL/min. INR ≤1.5 x ULN and aPTT ≤1.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify